Who is sponsoring NCT04432805?

NCT04432805 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT04432805?

Interventions in NCT04432805: Performing of lung ultrasound.

What condition does NCT04432805 study?

NCT04432805 studies Pregnant Women Suspected of COVID-19.

Is NCT04432805 still recruiting?

NCT04432805 is currently terminated. Last updated 12 August 2022.

Last reviewed 2022-08-12 · How we verify

NCT04432805: LUSCOVIDPREG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19

Terminated NA Last updated 12 August 2022

What this trial tests

NA trial testing Performing of lung ultrasound in Pregnant Women Suspected of COVID-19 in 2 participants. Terminated before completion.

Timeline

13 October 2020

Primary endpoint
2 January 2021

2 January 2021

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	2
Start date	13 October 2020
Primary completion	2 January 2021
Estimated completion	2 January 2021
Sites	1 location across France

Drugs / interventions tested

Performing of lung ultrasound

Conditions studied

Pregnant Women Suspected of COVID-19 — all drugs for Pregnant Women Suspected of COVID-19 →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, female only, with Pregnant Women Suspected of COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cohort prospective study. Objectives : Primary objective: To describe the lung ultrasound lesions in pregnant women in case of suspected or confirmed COVID-19 Secondary objectives: * To compare the lung ultrasound lesions with chest Computed Tomography -scanner (CT-Scan) lesions * To evaluate the performances of the lung ultrasound to diagnose COVID-19 in pregnant women * To evaluate predictive value of different lung ultrasound lesions for intensive care unit admission of pregnant women with suspected or confirmed COVID-19 * To describe the pregnancy issues of the study population Course of the study: * Inclusion of pregnant suspected of having COVID-19 and cared following the service protocol * Performing of lung ultrasound at bedside in labor ward or in COVID unit Primary outcome: Lung ultrasound lesions (and corresponding score) at the moment of the initial management of pregnant women suspected or confirmed with COVID-19 (having a nasopharyngeal Reverse Transcription Polymerase Chain Reaction (RT-PCR) SARS-CoV-2 and a chest CT-scan)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04432805 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 12 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04432805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing